Jun 04, 2020
Taiho Oncology To Present Data on Futibatinib (TAS-120) at the AACR Annual Meeting 2020
Apr 19, 2020
Innovent Biologics Announces FDA Approval of Pemazyre(TM) (Pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma
Oct 20, 2019
Innovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma
Apr 01, 2019
Preclinical Data Demonstrates the Potential of QED Therapeutics' Infigratinib in Multiple FGFR+ Tumor Types
Feb 14, 2019
Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II Study Evaluating Debio 1347 in Advanced Solid Tumors Harboring an FGFR fusion
Dec 16, 2018
Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China
Dec 10, 2018
QED Therapeutics Announces a Collaboration with Foundation Medicine to Develop Companion Diagnostics for Infigratinib
Oct 19, 2018
QED Therapeutics Presents Data for Infigratinib in Cholangiocarcinoma in Late Breaking Abstract at the European Society of Medical Oncology 2018 Congress
May 08, 2018
FDA Grants Fast Track Designation to Debiopharm International's Debio 1347 for the Treatment of Patients With Unresectable or Metastatic Tumors With a Specific FGFR Gene Alteration
Sep 10, 2017
Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma